Thank You Again for Contributing to the First-Ever Hemophilia Hackathon!

A three-day event designed to create a better future for the hemophilia community

October 20–22, 2017

Cambridge, Massachussetts

Hack to Change Lives

Teams identified a problem that matters to them—and worked to find a solution in just 48 hours.

CSL Behring and The National Hemophilia Foundation partnered with MIT Hacking Medicine to bring dedicated, passionate people from across the country to tackle the most pressing problems facing those who spend every day living with hemophilia.

We tackled this challenge together!

Members of the hemophilia community, as well as developers, designers, engineers, clinicians, and others came together in Cambridge to hack hemophilia-related questions during this weekend-long event. They used their expertise to pitch a problem, identify a solution, and help change lives.

Cambridge, MA


Spread the Word

Want to start helping right now?

Share our event with others by posting on your Twitter and Facebook feeds:

CSL Behring, Biotherapies for Life

For over a century, CSL Behring has developed innovative therapies to save and improve the lives of people with serious and rare diseases. We are a patient-focused company with over 30 years of experience working hand in hand with the hemophilia community.

National Hemophilia Foundation for all bleeding disorders

The National Hemophilia Foundation (NHF) is dedicated to finding better treatments and cures for inheritable bleeding disorders and to preventing the complications of these disorders through education, advocacy, and research.

MIT Hacking Medicine

MIT Hacking Medicine is a group of students, faculty, alumni, and community members whose goal is to energize, infect, and teach healthcare entrepreneurship and digital strategies to scale medicine as a way to solve health problems worldwide.

You are now leaving the current website.

You are about to leave You are accessing a CSL Behring site containing information about products marketed by the company.

Do you want to continue?

You are now leaving the current website.

The site you are accessing is maintained by a third party over whom CSL Behring has no control. CSL Behring does not review, approve, or necessarily endorse viewpoints, inferences, or conclusions stated in or implied by the content of this site. CSL Behring is not responsible for third-party content or the consequences of your use thereof.

Do you want to continue?